Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT06583564
Enrolling by invitation Not applicable

The Prognosis Effect of Indocyanine Green (ICG) Fluorescence Guided Surgery on Disease-free Survival (DFS) of Stage III Colorectal Cancer

NCT06583564 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai Tong Ren Hospital
Phase
Not applicable
Started
2024-09-27
Last updated
2026-06-22

Condition(s) studied

Colorectal Cancer Stage III

Investigational drug(s) / intervention(s)

ICG lymphangiography procedure

ICG lymphangiography procedure: All patients underwent standard complete mesocolic excision (CME) or total mesorectal excision (TME) with curable purpose using ICG lymphangiography procedure

Study summary

Previous studies of Indocyanine green (ICG) in colorectal surgery have focused on lymphatic mapping, lymph node detection, and the number of harvested lymph nodes. However, relatively few studies have evaluated the outcomes of this imaging technology, especially the prognosis following of colorectal cancer resection. The present study assessed the prognosis of stage III colorectal cancer patients following ICG fluorescence-guided surgery as compared to conventional surgery without the use of ICG Fluorescence imaging

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * age \> 18 years, * confirmed diagnosis of primary CRC, * preoperative tumor stage of cT1 to cT4, N+, M0 as determined by contrast-enhanced computed tomography (CT), * no distant metastasis, and * American Society of Anesthesiologists(ASA)Physical Status Classification score of 1, 2, or 3 Exclusion Criteria: * history of previous colorectal surgery, emergent surgery, or palliative resection; * pregnancy or breastfeeding; * allergy or history of an adverse reaction to ICG * severe mental disorder.

Primary outcome measure(s)

  • Disease-free survival (DFS) rate — From radical surgery to the end of follow-up ,up to 36 months
    the rate of of no recurrence or metastasis after 3 years from radical surgery

Trial sites (1)

FacilityCityRegionStatus
Shanghai Tongren Hospital Changning Shanghai Municipality

More Shanghai Tong Ren Hospital trials in China

Posterosuperior Bundle Pacing for Prevention of Atrial Fibrillation in Patients With Sinus Node Dysfunction Recruiting
Immediate Electrophysiological Effects of Different Atrial Pacing Sites on P-Wave Characteristics Recruiting
A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia Recruiting
Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium Infarction Recruiting
Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results Recruiting

Other trials for the same condition

Stage II/III Colorectal Cancer Recurrence Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06583564 on ClinicalTrials.gov ↗ ← All trials in China